Axsome Therapeutics (AXSM) Capital Leases (2024 - 2026)

Axsome Therapeutics has reported Capital Leases for 3 years, with the latest figure at $5.8 million in Q1 2026.

• Quarterly Capital Leases rose 58.8% year-over-year to $5.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.8 million (up 58.8% YoY) and the FY2025 annual result came in at $4.2 million, up 42.92% from the prior year.
• Capital Leases climbed to $5.8 million in Q1 2026 per AXSM's latest filing, from $4.2 million in the prior quarter.
• Over five years, Capital Leases peaked at $5.8 million in Q1 2026 and troughed at $1.7 million in Q1 2024.
• A 3-year average of $3.6 million and a median of $3.7 million in 2025 frame the typical range for Capital Leases.
• The widest YoY moves for Capital Leases: up 116.85% in 2025, down 25.36% in 2025.
• Over 3 years, Capital Leases stood at $2.9 million in 2024, then soared by 42.92% to $4.2 million in 2025, then soared by 38.94% to $5.8 million in 2026.
• According to Business Quant data, Capital Leases over the past three periods registered $5.8 million, $4.2 million, and $4.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.